BFRI · Biofrontera Inc. · Webcasts, Transcripts & Audio
$0.93
+0.04 (+4.61%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that these conditions raise substantial doubt about the Company's ability to continue as a going concern for at least twelve months from the issuance date of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 13, 2026
Market Cap
$16.19M
Shares
14.85M
Volume · Oct 6
390.34K
Avg daily vol (3M)
564.81K
Biofrontera Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Biofrontera Inc. (BFRI), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼0.3%
$4.32M
−$2.57M
'22 Q3
22-11-14
▲10.7%
$10.14M
−$2.79M
'22 Q4
23-03-08
▼10.4%
$8.73M
−$7.48M
'23 Q1
23-05-12
▲31.2%
$5.85M
−$9.84M
'23 Q2
23-08-11
▲105.8%
$8.90M
−$6.34M
'23 Q3
23-11-09
▲4.4%
$10.59M
$3.53M
'23 Q4
24-01-11
▼9.4%
$7.91M
−$10.44M
'24 Q1
24-05-15
▲34%
$7.84M
−$257,000
'24 Q2
24-08-14
▲1.3%
$9.01M
−$5.67M
'24 Q3
24-11-13
▲18.5%
$12.56M
−$1.40M
'24 Q4
25-03-21
▲8.5%
$8.59M
−$4.20M
'25 Q1
25-05-15
▲15.2%
$9.03M
−$5.32M
'25 Q2
25-08-13
▼22.5%
$6.99M
−$6.65M
'25 Q3
25-11-13
▲36.2%
$17.10M
$5.64M
'25 Q4
26-03-19
▲17.4%
$10.08M
−$4.75M
'26 Q1
26-05-14
LATEST
▲32.9%
$12.00M
−$604,000
'26 Q2
26-08-13
Earnings call
FY26 · Q2
2026-08-13
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call
Revenue
$12.00M
▲ 32.9% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript
Confident tone
Business transformation and cost structure
Pipeline and clinical development
AK label expansion
Revenue
$10.08M
▲ 17.4% YoY Diluted EPS
$-0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript
Confident tone
Loss reduction and path to breakeven
Clinical pipeline and regulatory milestones
Strategic transaction with Biofrontera AG
Revenue
$17.10M*
▲ 36.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript
Revenue
$6.99M
▼ 22.5% YoY Diluted EPS
$-0.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Biofrontera Inc. (BFRI) Q2 2025 Earnings Call Transcript
Confident tone
Record H1 2025 sales results
Restructuring of Biofrontera AG relationship
Acne vulgaris Phase II trial
Revenue
$9.03M
▲ 15.2% YoY Diluted EPS
$-0.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript
Confident tone
Ameluz formulation patent
Label extension clinical trials
Acne indication (Phase II)
Revenue
$8.59M
▲ 8.5% YoY Diluted EPS
$-0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-21
Biofrontera Inc. (BFRI) Q4 2024 Earnings Call
Revenue
$12.56M*
▲ 18.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript
Confident tone
RhodoLED XL lamp launch
Revenue growth and Hurricane Milton impact
Clinical trial progress in new indications
Revenue
$9.01M
▲ 1.3% YoY Diluted EPS
$-0.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript
Confident tone
Revenue growth and quarterly sales performance
Clinical trials and pipeline expansion
Balance sheet and debt repayment
Revenue
$7.84M
▲ 34% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-15
Biofrontera Inc. (BFRI) Q1 2024 Earnings Call Transcript
Confident tone
Ameluz license and supply agreement renegotiation
Clinical trials and FDA submissions
Change Healthcare cyberattack impact on Q1 revenue
Revenue
$7.91M
▼ 9.4% YoY Diluted EPS
$-2.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-11
Biofrontera Inc. (BFRI) Q4 2023 Earnings Call Transcript
Confident tone
Ameluz and PDT product strategy
Product launches and patents
Financing and balance sheet
Revenue
$10.59M*
▲ 4.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Biofrontera Inc. (BFRI) Q3 2023 Earnings Call Transcript
Revenue
$8.90M
▲ 105.8% YoY Diluted EPS
$-4.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-11
Biofrontera Inc. (BFRI) Q2 2023 Earnings Call Transcript
Revenue
$5.85M
▲ 31.2% YoY Diluted EPS
$-7.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-12
Biofrontera Inc. (BFRI) Q1 2023 Earnings Call Transcript
Revenue
$8.73M
▼ 10.4% YoY Diluted EPS
$-5.60
▼ 187.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-08
Biofrontera Inc. (BFRI) Q4 2022 Earnings Call Transcript
Revenue
$10.14M*
▲ 10.7% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Biofrontera Inc. (BFRI) Q3 2022 Earnings Call Transcript
Revenue
$4.32M
▼ 0.3% YoY Diluted EPS
$-2.26
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-12
Biofrontera Inc. (BFRI) Q2 2022 Earnings Call Transcript
Revenue
$4.46M
▼ 23.9% YoY Diluted EPS
$-0.90
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-13
Biofrontera Inc. (BFRI) Q1 2022 Earnings Call Transcript
Revenue
$9.75M
▲ 105.5% YoY Diluted EPS
$6.40
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-18
Biofrontera Inc. (BFRI) Q4 2021 Earnings Call Transcript
Revenue
$9.17M*
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-30
Biofrontera Inc. (BFRI) Q3 2021 Earnings Call Transcript
Revenue
$4.33M
▲ 33.3% YoY Diluted EPS
$-40.00
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–20 of 20 webcasts